Business UpdateMay 19, 2026, 10:30 AM
NeOnc Technologies Gains Analyst Coverage, Insider Buying Nears $1M
AI Summary
NeOnc Technologies, a clinical-stage biotechnology company, is attracting significant attention from Wall Street analysts, institutional investors, and company insiders. Several firms, including Maxim Group and BTIG Research, initiated favorable coverage with advantageous ratings. CEO Amir Heshmatpour has consistently purchased shares, with recent acquisitions exceeding $500,000 and cumulative insider buying approaching $1 million over the past year. Institutional ownership is also expanding, with firms like Bank of America increasing positions, ahead of anticipated interim data for its lead brain cancer candidate, NEO100.
Key Highlights
- CEO Amir Heshmatpour's recent share purchases totaled over $500,000.
- Cumulative insider purchases by the CEO approach $1 million over the past year.
- Maxim Group, Alliance Global Partners, and BTIG Research initiated favorable coverage.
- Institutional ownership expanded with firms like Bank of America and State Street Corp.
- Lead candidate NEO100 is in a fully enrolled Phase 2a clinical trial.
- Interim data for NEO100 is expected in the near term.
Price Impact
More from NTHI